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Abstract
We attempted to validate a two-stage strategy to screen for severe obstructive sleep apnea 
syndrome (s-OSAS) among hypertensive outpatients, with polysomnography (PSG) as the gold 
standard. Using a prospective design, we recruited outpatients with hypertension from medical 
outpatient clinics. Interventions included: 1) assessment of clinical data; 2) home sleep testing 
(HST); and 3) 12-channnel, in-laboratory PSG. We developed models using clinical or HST data 
alone (single-stage models) or clinical data in tandem with HST (two-stage models) to predict s-
OSAS. For each model, we computed area-under-receiver-operating-characteristic curves (AUC), 
sensitivity, specificity, negative likelihood ratio, and negative post-test probability (NPTP). 
Models were then rank-ordered based upon AUC values and NPTP. HST used alone had limited 
accuracy (AUC=0.727, ,NPTP = 2.9%). However, models that used clinical data in tandem with 
HST were more accurate in identifying s-OSAS, with lower NPTP: 1) facial morphometrics 
(AUC=0.816, NPTP=0.6%); 2) neck circumference (AUC=0.803, NPTP=1.7%); and 
Multivariable Apnea Prediction Score (AUC = 0.799, NPTP =1.5%) where sensitivity, specificity 
and NPTP were evaluated at optimal thresholds. Therefore, HST combined with clinical data can 
be useful in identifying s-OSAS in hypertensive outpatients, without incurring greater cost and 
patient burden associated with in-laboratory PSG. These models were less useful in identifying 
OSAS of any severity.
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Obstructive sleep apnea (OSA) affects approximately one third of individuals with 
secondary hypertension and is one of its major identifiable causes.1 Large-scale studies that 
associated2 and implicated OSA in the development of incident hypertension3 support this 
designation, even after controlling for obesity, a major risk factor for OSA. Some 
randomized trials have shown that treating OSA with positive airway pressure (PAP) 
reduces blood pressure,4–7 particularly if OSA is severe and participants are sleepy.4, 5, 8–11 
These results, along with the high prevalence of OSA among sufferers of hypertension, 
support screening patients with hypertension for severe sleep obstructive sleep apnea 
syndrome (s-OSAS; severe OSA associated with sleepiness).12
In-laboratory polysomnogram (PSG) is unsuitable for screening13 due to complexity, 
expense, and inaccessibility. Signs and symptoms may identify persons at risk for OSA,14, 15 
using questionnaires.16 While particularly useful in lean subjects,16 symptoms are often 
nonspecific or under-reported. Facial morphometrics17 have not added predictive value to 
body mass index (BMI, a proxy for obesity), which has been used for risk assessment. In 
2005, the American Academy of Sleep Medicine (AASM) deemed current clinical models 
insufficient for predicting apnea severity.18
We previously validated a two-stage screening tool for OSA.19, 20 We first applied a risk 
score that combined data from symptoms, age, gender, and BMI to everyone. In the second 
stage, we conducted overnight oximetry in a subset at intermediate risk. Portable sleep 
monitors21 that assess respiratory effort and airflow in addition to oximetry22 have since 
become available, allowing for unattended home sleep testing (HST).
In the current study, we used HST to validate our two-stage model in hypertensive 
outpatients. We screened for s-OSAS since the greatest benefits from PAP, including 
reduction in BP 4, 9, 10 and cardiovascular event-rates, 23 occur in this group. The two-stage 
screening tool was also applied to hypertensive patients with any OSA associated with 
sleepiness, regardless of OSA severity.
Methods
The Institutional Review Boards of the University of Pennsylvania and Philadelphia VA 
Medical Centers approved this protocol. All subjects provided informed consent.
Subject selection
We recruited consecutive outpatients with hypertension aged 30–65 years from internal 
medicine practices at the Philadelphia VA Medical Center and the Hypertension Clinic at 
the University of Pennsylvania. We defined hypertension as systolic BP ≥140 mm Hg, 
diastolic BP ≥90 mm Hg, or the use of any antihypertensive medication.2 We excluded those 
who had prior PSGs, or could not participate because of self-reported illness, pain, or 
circadian sleep disturbances (Figure 1).
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Interventions offered for all subjects
1. Demographics, Apnea Symptoms, Physical Examination
Demographics, symptoms, tobacco and alcohol use, and the Epworth Sleepiness Scale 
(ESS)24 were self-reported. We measured BMI and neck circumference (NC).
2. Facial Morphometrics Score combined BMI, NC, degree of overjet of the maxilla over the 
mandible, palatal height, and intermolar width. Higher scores signified greater apnea risk.17
3. Home Sleep Testing (HST) (AutoSet PDS, ResMed Corp., San Diego, CA) consisted of 
unattended pulse oximetry, chest and abdominal movement, and airflow by nasal pressure 
for one night. Following technician-led instruction, subjects self-applied the sensors at 
home, wore them for one night, and returned them in-person. We applied the AutoSet’s 
automated scoring algorithm to downloaded data 25, which used a 50% drop in airflow from 
the baseline to define a hypopnea and a 75% drop in airflow for ≥10 seconds for an apnea. 
Desaturation was not required to score apneas or hypopneas.25 Therefore, while oximetry 
was worn according to the manufacturer’s protocol, it was not used in automated scoring. 
We chose in-home monitoring and automated scoring to reflect typical clinical practice.
4. In-laboratory PSG recorded electro-encephalograms, eye, chin and pre-tibial muscle 
activity, electrocardiography, oximetry, chest and abdominal respiratory effort, and airflow 
by nasal cannula and oral thermistor (Formerly Sandman System, nowEmbla® Systems Inc, 
Broomfield, CO). Technicians performed PSGs prospectively, after questionnaires and 
unattended sleep studies, while blind to questionnaire data, apnea risk scores, facial 
morphometrics, and unattended sleep study data. They scored PSGs26 and computed the 
apnea-hypopnea index (AHI) as ([apneas+hypopneas]/hours of sleep time). An apnea was 
≥10 seconds of airflow cessation. A hypopnea required ≥10 seconds of reduction in airflow: 
1) either ≥50%, or 2) ≥30% with ≥4% fall in SaO2 or an arousal.
Missing Data
We conducted multiple imputation for missing age, BMI, NC, ESS, symptoms, PSG AHI 
and unattended HST AHI (uAHI) values using a well-validated method,27 using PROC MI 
(SAS Systems, Cary, NC).
Case definition
We defined a case of s-OSAS as AHI≥30events/hour + ESS>10.8 Alternatively, we 
considered AHI≥5 events/hour + ESS>10 as any case of OSAS.
Risk assessment
For all subjects with available data, we assessed risk via single- and two-stage strategies:
1. Single-stage strategies (risk scores): Our base model, the multivariable apnea prediction 
(MVAP) score, combined symptoms, BMI, age, and gender to compute s-OSAS risk.16 To 
elucidate symptoms, subjects self-rated their frequency of snoring, choking, and witnessed 
apneas on a Likert scale, range=0–4. We combined this score with BMI, age, and gender 
using a previously validated16 multiple logistic regression (SAS v9.2, Cary, NC) and 
Gurubhagavatula et al. Page 3













obtained a risk score (range=0–1, 1=high risk, 0=absent risk for s-OSAS). Individual 
analyses for BMI, NC, age, facial morphology, and symptoms were also completed.
2. Two-Stage Strategies
First stage: We categorized subjects into high, intermediate or low risk groups based on their 
first-stage test score (e.g. the MVAP). “Upper bound” separated high from intermediate risk 
groups. “Lower bound” separated intermediate from low risk groups (FIGURE 2; see 
“Model development and validation” below). We predicted that those with risk score>upper 
bound would have s-OSAS, and those with risk score<lower bound would not.
Second stage: Those with intermediate scores (between upper and lower bound) were 
predicted to have s-OSAS if the uAHI was >“uAHIthreshold.” If uAHI <uAHIthreshold, they 
were predicted to be free of s-OSAS.19 The analysis was repeated for any patient with 
OSAS regardless of severity.
Model development and validation
While single-stage strategies had a single parameter (i.e., cut-point), two-stage strategies had 
three parameters: the upper and lower bounds and the uAHIthreshold. The “optimal” 
parameter set minimized misclassification rate and maximized specificity; we identified it 
using an exhaustive enumeration algorithm with SAS v9.2 (Cary, NC) (see below). Using 
this “optimal” parameter set, we computed sensitivity, specificity, negative likelihood ratio 
(LRneg),28 and negative post-test probability in a randomly-selected 70% estimation sample 
and in the remaining 30% validation sample. We also computed the AUC29 in both samples. 
Using bootstrap resampling, we generated 95% confidence intervals (CI’s) for AUC, 
sensitivity, specificity, and LRneg.
Determination of the optimal cut-points for the single-stage strategies
We first selected 9 candidate cut-points for each model that divided the sample into 10 
groups of equal number. For each candidate cut-point, we calculated error rate as (FP + 1.2 
X FN). We weighted false negatives (missed cases) at 1.2 times the false positives, because 
we presumed that missing cases of severe OSAS was a more serious error than falsely 
labeling a normal patient with severe OSAS. In sensitivity analyses, we considered values 
from 1.0–2.0 in increments of 0.1. We chose 1.2 when our sensitivity analysis showed that 
higher weights did not improve the LRneg. The optimum cut-point was identified as the one 
that minimized this error rate. In cases of ties, the solution that maximized specificity was 
chosen. We have outlined this rationale elsewhere.30, 31
Determination of the optimal cut-points for the two-stage strategies
The two-stage strategy had three parameters: the upper and lower bounds of the first stage 
test and uAHIthreshold. We considered six uAHI-thresholds: 5, 10, 15, 20, 25, and 30/hour. 
For the first stage test, we considered candidate cut-points (9 upper and 9 lower bound 
values) as described for the single-stage strategies. Thus, we considered a total of 
6X9X9=486 possible parameter sets and computed (FP + 1.2 X FN) for each parameter set. 
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We selected the optimum parameter set as the one that minimized this error rate and 
maximized specificity.
Quantification of the discriminatory power of each model
Using the optimum cut-points of each of the models, we computed sensitivity, specificity 
and LRneg. We computed LRneg as (1-sensitivity)/specificity. We computed the negative 
post-test probability associated with LRneg, after applying a Bayesian formula and the 
prevalence of OSA in a 70% estimation sample (6.9%). We also computed a prediction 
discrimination index as the area under receiver-operating-characteristic curve (AUC) 
constructed from the logistic model predicted values. For the 30% validation sample, this 
was done using the formula AUC = (D+1)/2, where D represents the Somer’s D statistic of 
the proc logistic function. We rank-ordered the discriminatory power of the models by 
sorting them based on the value of AUC, with larger values of AUC denoting the best-
performing models. The AUC for each model is an estimate of the probability that a 
randomly selected case has a larger predicted value than a randomly selected control.
Generation of non-parametric 95% bootstrap confidence limits
Using the estimation cohort, we generated 1000 bootstrap re-samples with replacement via 
SAS programming. For each re-sample, we computed 1) AUC and 2) the optimum cut-point 
and its associated sensitivity, specificity and LRneg. We selected from these distributions the 
2.5th and 97.5th percentile values of AUC, sensitivity, specificity, and LRneg to define the 
95% non-parametric confidence limits.
Model validation
We computed percent difference as (AUC in validation sample – AUC in estimation 
sample)/(AUC in estimation sample). We categorized models as “robust” if this percent 
difference in AUC between validation and estimation samples was ≥ −5%, and “not robust” 
if this percent difference in AUC was <-5%. The optimal model was the one which was 
robust and had the highest AUC.
Results
Subject characteristics
We enrolled 250 patients (Table I) after excluding those with self-reported pain (N=7), 
medical illness (N=7), jet lag (N=2), or night shift work (N=19). Sample, estimation, and 
validation subsets were similar, except for a larger percentage of Caucasians in the 
estimation subset. The average (SD) age, NC, and BMI were: 52.6 (7.7) years, 42.2 (4.5) 
cm, and 32.1 (7.4) kg/m2 respectively. S-OSAS and any OSAS frequency distribution by 
BMI category is shown (FIGURE 3). In the subjects with and without s-OSAS, the average 
(SD) blood pressures were 145/87 (12/11) and 139/82 (15/10), respectively.
Apnea risk
The mean (SD) for MVAP scores (n=224) was 0.53 (0.25). The mean (SD) morphometric 
score (n=160) was 68.5 (24.7); the score could not be computed for remaining participants 
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due to missing molars. Whereas a score of ≥70 carried 98% sensitivity and 100% specificity 
in a prior study,17 in our study, the optimal cut-point of 80 yielded sensitivity of 66.9%, 
specificity of 70.1% and negative post-test probability of 0.6% for s-OSAS.
In-lab sleep studies
Of 198/250 (79.2%) who agreed to in-lab PSG, 159 (80%) had OSA: 67 (34%) mild (AHI 
5–14.9/hour); 43 (22%) moderate (AHI 15–29.9/hour); 49 (25%) severe (AHI≥30/hour). 
Sleepiness (ESS>10) occurred in 62/242 (25.6%). A total of 49 patients (24.7%) had at least 
mild OSAS (AHI≥5/hour plus ESS>10), and 15 patients (7.6%) had s-OSAS (AHI ≥30/hour 
plus ESS>10) (Table I). The cohort’s mean (SD) AHI was 22.5 (22.9)/hour.
Unattended sleep studies
Of 208 subjects who agreed to unattended HST, 192 had adequate recordings. Of these, 
76.9% had usable data after one attempt, and an additional 20.2% after a second attempt. 
The mean (SD) uAHI was 15 (13.8)/hour. A total of 25.7% had uAHI ≥5/hour with ESS 
>10, and 6% had uAHI ≥30/hour with ESS >10. Unattended HST underestimated in-
laboratory AHI for values between 33 – 45/hour (Figure 4).
AUCs and percent difference: s-OSAS
AUCs in the estimation and validation subsets are listed for single-stage and two-stage 
models, along with percent difference between those subsets (Table II). All single-stage 
models were robust, with percent difference ranging from −0.1% to 13.3%, and all (except 
age) had similar discriminatory power, with AUCs ranging from 0.663 for symptoms to 
0.689 for NC (most useful). Age was not a useful single-stage model, with an AUC of 0.463.
The two-stage models (Table II) using HST in the second stage were more accurate than 
one-stage models, with higher AUC values ranging from 0.718 (age) to 0.816 
(morphometrics). The most useful one-stage model, NC, performed better when combined 
with unattended sleep studies, yielding an AUC of 0.803. The top 3 performing two-stage 
models (AUC’s near or above 0.800) were NC, morphometrics, and MVAP.
Accuracy of models: sensitivity, specificity, negative post-test probability: s-OSAS
We report the accuracy of these single- and two-stage models (Table III, upper and lower 
panels, respectively). In the single-stage model, use of MVAP ≥0.483 had the greatest 
sensitivity for detecting s-OSAS (91.5%), and the second-lowest NPTP for s-OSAS (1.5%). 
Use of NC ≥42.6 cm had similar sensitivity (85.6%) and NPTP (1.7%). Facial 
morphometrics score ≥ 80.0 offered the highest specificity (70.1%) but the second-lowest 
sensitivity (66.9%) for detecting for s-OSAS, with the lowest NPTP of s-OSAS among 
single stage models (0.6%).
For unattended sleep studies used alone (Table IV), the optimal cut-point for detecting S-
OSAS was 16 events/hour with sensitivity=74.7%, specificity=70.6%, LRneg=0.357 and 
NPTP= 2.9%.
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We evaluated HST when it was used in tandem with one stage models (MVAP, NC, facial 
morphometry). The optimal upper and lower bounds for these first-stage tests, and optimal 
cutpoint for HST are shown in Table III, lower panel. We found that: 1) MVAP followed by 
HST had 88.2% sensitivity, 71.6% specificity, and NPTP of 1.5%. 2) NC followed by HST 
had sensitivity of 83.6% and specificity of 77.0% with a NPTP of 2.0%. 3) Facial 
morphometry followed by HST identified s-OSAS with 94.2% sensitivity, 68.9% 
specificity, and NPTP of 3.7%, but morphometry was not feasible in 64/224 (28.6%) 
because of the absence of teeth.
Accuracy of Models: Any OSAS
AUCs in the estimation and validation subsets using criteria for any OSAS (AHI ≥ 5 events/
hour; ESS>10) are listed for single-stage and two-stage models (Table V). This definition 
yielded a higher prevalence of 22.9%. All models were less useful for predicting any OSAS 
than for predicting s-OSAS.
Unattended HST was not useful in case-finding any OSAS (AUC=0.591). (Table IV). 
Overall, two-stage models that screen for any OSAS (Table V, lower panel) were 
significantly less useful than two-stage models that screen for s-OSAS (AUC range = 0.606–
0.672 vs. 0.718–0.816, respectively; Table III, lower panel).
Missing data
Multiple imputation did not introduce significant bias. Percent difference in AUC between 
pre-imputation and post-imputation data was minimal (0.2% for NC) to absent (all other 
single-stage models).
Discussion
Among hypertensive outpatients, between 30 and 40% have OSA.32 Our case definition, 
severe OSAS with sleepiness, was selected based on data from the Sleep Heart Health Study 
(SHHS),11 which suggested that self-reported sleepiness may indicate susceptibility to 
cardiovascular sequelae of OSA and mark patients who should receive treatment priority. 
Blood pressure reduction may also be greater in OSA patients who receive PAP treatment 
and report sleepiness.4, 9, 10 Even with this added criterion, the proportion of our cohort with 
s-OSAS was nearly twice that of other middle-aged populations.33 This finding is not 
surprising, given the high prevalence of risk factors for OSA among veterans, including 
hypertension, obesity, male gender, African-American race, and habitual alcohol 
consumption (Table I).34
Single-stage models with the best discriminatory power in screening for s-OSAS were NC, 
facial morphometrics, and MVAP. MVAP and NC proved particularly good screening tools 
with sensitivities of 91.5% and 85.6% respectively at optimal cut points of MVAP = 0.483 
and NC = 42.6 cm. Morphometry was less feasible than MVAP or NC because 28.6% of the 
sample lacked first, second or third molars, so intermolar distance could not be measured to 
compute the facial morphometry score. Given the relative ease of measuring NC in routine 
clinical practice, our findings support to its utility for initial patient evaluation for s-OSAS.
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Despite its mathematical complexity,16 the MVAP can be computed using mobile, desktop, 
or web-based applications using easily-obtainable clinical information, which makes the 
MVAP a viable option in mass s-OSAS screening. MVAP calculation also lends itself well 
to emerging technologies such as sleep telemedicine, where BMI, gender, age, and 
symptoms can be obtained remotely and used to obtain the risk score.
Each of the three top-performing single-stage models demonstrated improved discriminatory 
power when used in tandem with HST. Facial morphometrics followed by HST showed the 
best power (AUC = 0.816), although NC and MVAP were almost as powerful in the two-
stage models (AUCs = 0.803 and 0.799 respectively). In all models, combining easily-
obtainable clinical information combined with HST (cut point AHI = 16 events/hour) 
increased discriminatory power with higher AUC values.
We evaluated the impact two-stage algorithms would have on the volume of in-laboratory 
PSGs. The two-stage models using NC, MVAP or BMI were negative for s-OSAS 66–67% 
of the time. Given a missed case rate of only 0.5–1% in this group, one could argue that 
confirmatory PSGs are probably not justified on an economic basis, unless the cost of 
missing a case proved to be inordinately high. A reduction in in-laboratory PSGs by 66–67% 
may not only lower diagnostic costs, but also reduce patient burden, while increasing 
availability and accessibility of in-laboratory studies for those who are not candidates for 
unattended studies. Given the potential for adverse health effects of missing cases, the low 
missed case rate is a desirable feature of this program.
All models had less discriminatory power when we considered OSAS cases of any severity. 
HST alone was marginally useful, with an AUC of only 0.591 for identifying any OSAS. 
Adding clinical data to these studies improved accuracy in finding any OSAS only 
modestly; AUCs range 0.606–0.672 for two-stage models.
Our hypopnea definition did not require desaturation; this liberal definition is appropriate 
because it reduces the likelihood of missing cases during screening. Used for Medicare 
coverage for PAP, definitions that require a desaturation12 would lower disease prevalence, 
and therefore improve the negative predictive value of our screening models. Additionally, 
our study reveals a modest decline in HST sensitivity for detecting any OSA (AHI ≥5 
events/hour) when pulse oximetry is not considered. HST devices incorporating pulse 
oximetry have sensitivity of at least 82.5% for detecting any OSA,35 while our AutoSet-
based scoring had 74.7% sensitivity.
Feasibility
We conducted unattended sleep studies in 208/250 (83.2%) subjects. We obtained usable 
data in 192/208 (92.3%). Only 48/208 (23.1%) required repeat testing. Similar failure rates 
were found in another study.36 Future monitors may be simpler to assemble, yet more 
accurate and successful. While we obtained BMI, NC, and symptom scores in nearly 
everyone, absent molars precluded us from obtaining morphometric scores in nearly one-
third.
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Comparison with prior studies and limitations in design
Symptoms were useful in our cohort, contrasting with other sleep-center cohorts.16 In our 
non-referral, more obese group, symptoms added robustness to the results, yielding 
comparable AUC’s in the validation and estimation samples. Thus, symptoms may be useful 
in general populations outside of sleep centers who have a high prevalence of OSA-related 
risk factors. Symptom data may be less useful, however, in occupational screening, where 
reporting may be inaccurate.19
BMI was a powerful predictor of OSA in prior studies,17, 19 with AUCs of 0.938 and 0.802, 
respectively. BMI was less useful in our program, with AUC of 0.665. We calculated the 
coefficient of variation (CV=SD/mean*100%) to assess whether BMI was less useful in our 
group due to lower variance. However, CV =22.9% in our study was comparable to 
CV=23.1% elsewhere.17 We surmise that unmeasured risk factors for OSA among the non-
obese patients in our group may have reduced the utility of BMI in this study. Additionally, 
exclusion of non-hypertensive patients may have degraded BMI predictive value.
HST tended to underestimate in-laboratory AHI for the 33–45 event/hour range. These 
findings are similar to those from previous work comparing HST and in-laboratory PSG.37 
AHI on PSG is calculated as the number of respiratory events per hour of sleep, while HST 
monitors report this index based on hours of use. Since HST cannot differentiate sleep from 
wakefulness, its respiratory indices may be lower than on PSG.
Additionally, our AutoSet device utilized only nasal cannula pressure changes to identify 
apneas and hypopneas, as opposed to full PSG which utilizes nasal pressure and an oronasal 
thermistor in respiratory event detection. When using nasal pressure alone (without a 
thermistor) to detect respiratory events, less-stringent criteria to score respiratory events may 
reduce missed cases without raising false positive rates.38 Monitors that use more stringent 
criteria for scoring events than those used by the AutoSet may miss more cases, and reduce 
the usefulness of unattended HST.
Strengths and Limitations
Ours is the first investigation of screening for OSAS among a general population of 
hypertensive outpatients, rather than sleep center referrals,22 with unattended recordings of 
airflow and respiratory effort at home (HST).21 The AASM has published guidelines22 and 
the Centers for Medicare and Medicaid Services has approved the use of this type of monitor 
for diagnosing OSA and initiating positive airway pressure (PAP) therapy.39 The strengths 
of this investigation include: 1) prospective application of HST and full PSGs, after 
administration of first-stage screening tools; 2) blinding of PSG scorers to all other clinical 
data; 3) the use of a general medical rather than subspecialty-based population; and 4) use of 
a definition of hypertension that is consistent with that used in prior investigations, such as 
the SHHS.2
Given that our sample was comprised largely of Caucasian and African-American men, 
additional studies are needed to refine these models for other ethnic groups in whom s-
OSAS may occur in thin individuals with intraoral or craniofacial risk factors,40–42 and 
symptoms may be more important.16 The limited proportion of women (20%) in this largely 
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veteran population reduces our ability to generalize these results to them. Similarly, while 
age was more useful in other settings, single-stage models that contained age in this cohort 
had AUC<0.7, perhaps because of the restriction of our sample to 30–65 years. Future 
evaluations of OSA screening strategies should include other ethnic, gender, and age groups.
Conclusions
Two-stage models can be used to screen for s-OSAS to reduce the requirement for in-
laboratory PSGs in hypertensive outpatients, a population with high disease prevalence.2 
Models utilizing a facial morphometric score, neck circumference, and the MVAP at 
optimal cut points as the first stage in these models demonstrated greatest utility. They are 
less helpful in screening patients for OSAS of any severity. Unattended HST works best 
when used in tandem with clinical data rather than used alone, particularly in screening for 
any OSAS, because of the high likelihood of missed cases.
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Figure 1. Flow Diagram
Abbreviations: PSG = polysomnogram; HST = home sleep test; MVAP = multivariable 
apnea prediction score
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Figure 2. Study Design
Abbreviations: HST = home sleep test; AHI = apnea-hypopnea index; s-OSAS = severe 
OSA associated with sleepiness
Gurubhagavatula et al. Page 14













Figure 3. Frequency distribution of OSAS by BMI category
Abbreviations: BMI = Body Mass Index; s-OSAS =severe obstructive sleep apnea syndrome
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Figure 4. Bland-Altman Analysis
Unattended sleep studies tended to underestimate in-laboratory AHI for an approximate 
value of 3.5 – 3.8 log units/hour, which corresponds to an average of portable AHI + PSG 
AHI of 33 – 45/hour. We used log transformation of the AHIs in our prediction models to 
reduce the undue influence of large values.
Abbreviations: AHI = Apnea-Hypopnea Index; uAHI = AHI from unattended home sleep 
test; PSG = polysomnogram
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   Mean Age (SD), years 52.6 (7.70) 52.6 (7.49) 53.2 (8.37) 0.95
   Men (%) 200 (80.0%) 119 (81.5%) 43 (82.7%) 0.48
   Caucasian (%) 101 (40.4%) 51 (34.9%) 15 (28.9%) 0.04
   African-American (%) 147 (58.8%) 95 (63.7%) 37 (71.2%) 0.06
Apnea Risk, Mean (SD)
   BMI, kg/m2 32.1 (7.36) 32.6 (7.35) 31.8 (6.37) 0.23
   NC, cm 42.2 (4.53) 42.5 (4.38) 42.0 (4.39) 0.23
   MVAP 0.53 (0.25) 0.56 (0.23) 0.49 (0.31) 0.06
   Morphometrics 68.5 (24.7) 69.7 (24.5) 70.9 (24.9) 0.45
Smokers (%)
   Current smokers 72 (28.8%) 38 (26.0%) 22 (42.3%) 0.25
   Ever smokers 83 (33.2%) 43 (29.4%) 24 (46.2%) 0.13
Blood Pressure, Mean (SD)
   Systolic 139.0 (14.9) 138.3 (15.0) 141.0 (14.5) 0.26
   Diastolic 82.2 (9.2) 82.5 (9.6) 81.4 (8.3) 0.48
Alcohol consumers (%)
   At least one drink/day 155 (61.8%) 86 (58.9%) 33 (63.4%) 0.25
   At least 12 oz beer per week 102 (40.6%) 56 (39.7%) 21 (40.4%) 0.74
   At least 4 oz spirit per week 68 (27.3%) 36 (25.0%) 17 (32.7%) 0.32
   At least 6 oz wine per week 71 (28.4%) 41 (28.4%) 16 (30.8%) 0.99
ESS score >10 62 (25.6%) 45 (31.0%) 17 (32.7%) 0.21
OSAS by PSG (%)
   Mild (AHI ≥5 & ESS>10) 49 (24.7%) 33 (22.8%) 16 (30.8%) 0.25
   Mod (AHI≥15 & ESS>10) 29 (14.7%) 20 (13.8%) 9 (17.3%) 0.54
   Severe (AHI≥30 & ESS>10) 15 (7.6%) 10 (6.9%) 5 (9.6%) 0.53
Abbreviations: SD = Standard deviation; BMI = body mass index; NC = neck circumference; MVAP = multivariable apnea prediction score; OSAS 
= obstructive sleep apnea syndrome; AHI = apnea-hypopnea index; ESS = Epworth sleepiness score; PSG = polysomnogram.
*
198 participants (146 in Estimation Sample + 52 in Validation Sample) underwent in-lab PSG.
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Table II
Relative Discriminatory Power and Robustness of Models Used in Single- and Two-Stage Algorithms 
(N=250)















































(0.444 – 0.481) (0.700 – 0.737)
Abbreviations: NC = neck circumference; BMI = body mass index; MVAP = Multivariable Apnea Prediction Score; AUC = area under the receiver 
operating characteristic curve; CI = confidence interval.
*
Model applied as first stage, followed by HST for those in intermediate risk group
**
Difference = (AUC in validation sample – AUC in estimation sample)/(AUC in estimation sample)
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